Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab + cetuximab reintroduction in RAS/BRAF wild-type advanced colorectal cancer
ChiCTR2300069490Phase 2Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Mar 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab and cetuximab in colorectal cancer (CRC), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: overall survival. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
toripalimabcetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2300069490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069490.